The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Venturi Wealth Management LLC purchased a new position in shares of argenx SE (NASDAQ:ARGX – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...